Acasti Pharma investor relations material

Acasti Pharma Inc., is an Canadian biopharmaceutical company that engages in the development and commercialization of pharmaceutical products for the treatment of dyslipidemia and cardiometabolic risk factors. Its lead drug candidate, CaPre, is a prescription-only medication for the treatment of hypertriglyceridemia. It offers CoregCR, a registered therapeutic formulation of carvedilol for the treatment of hypertension and heart failure for patients with chronic renal impairment.